2023 annual financial data
Lyell Immunopharma 2023 Operating cash flow margin
Direct answer
Operating cash flow margin was -125,918.46%.
Operating income was -247,008,000 USD and net income was -234,632,000 USD.
Operating cash flow was -163,694,000 USD.
Get free Lyell Immunopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 130,000 USD
- Operating income
- -247,008,000 USD
- Net income
- -234,632,000 USD
- Operating cash flow
- -163,694,000 USD